{"id":"W4383750469","doi":"10.21203/rs.3.rs-2966905/v1","title":"Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer-related gene regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; Eli Lilly Japan; Eisai; Puma Biotechnology; Howard Hughes Medical Institute; Cancer Prevention and Research Institute of Texas; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Welch Foundation; Susan G. Komen for the Cure; Daiichi Sankyo Europe; U.S. Department of Defense; Breast Cancer Research Foundation; Gilead Sciences","keywords":"Protein arginine methyltransferase 5; Cancer research; Arginine; Methyltransferase; Breast cancer; Cancer; Medicine; Pharmacology; Chemistry; Methylation; Internal medicine; Biochemistry; Amino acid; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001606598,0.0004576769,0.0004307177,0.0006020818,0.0002338888,0.0001573818,0.0005325218,0.000885448,0.0004378372],"category_scores_gemma":[0.0000663473,0.0004632069,0.0002323956,0.0008214609,0.0001977676,0.00001551737,0.00051284,0.001420512,0.00004696336],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007159548,"about_ca_system_score_gemma":0.001612391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004100395,"about_ca_topic_score_gemma":0.003032681,"domain_scores_codex":[0.9949932,0.0007109838,0.0005572666,0.001498264,0.001236358,0.001003956],"domain_scores_gemma":[0.9976202,0.00003650239,0.000123857,0.001200315,0.0007551113,0.0002640742],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00152159,0.0004609721,0.001490639,0.0009555676,0.0002351583,0.00002713843,0.0004341678,0.02588853,0.9620152,0.00008291622,0.002539741,0.004348415],"study_design_scores_gemma":[0.003712584,0.001621407,0.05778733,0.00286011,0.00008114165,0.00002192798,0.001481728,0.00887006,0.8671925,0.003466502,0.05072818,0.002176521],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982895,0.006030343,0.0004966575,0.004690774,0.0004951255,0.003150789,0.001981304,0.00008886185,0.0001711425],"genre_scores_gemma":[0.9905825,0.001436768,0.0001747755,0.00005403504,0.0009544709,0.001862122,0.001559316,0.0001650945,0.003210922],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09482266,"threshold_uncertainty_score":0.999782,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05096382593989946,"score_gpt":0.3742183991151543,"score_spread":0.3232545731752548,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}